We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Hayley
Brooks
hayley.brooks@mft.nhs.uk
Dr
Anthony
Wilson
anthony.wilson@mft.nhs.uk
Corie
Jackson
corie.jackson@mft.nhs.uk
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The EMBRaCE-GM study is a multi-cohort trial designed to efficiently evaluate the range of wearable vital signs monitors that could be used to support patients during cancer treatment.
The aims of the study are to determine
- to determine if continuous vital signs monitoring is feasible during cancer treatment
- to determine if such monitoring is acceptable to patients undergoing cancer treatment
- to determine what insights could be made with the data obtained
A multi-cohort study is essential because there are a huge range of vital signs monitors that could be useful and we need a method that allows us to quickly identify the devices that are most acceptable to patients and which offer the most useful information to clinicians. Similarly, the best device may vary according to the specific disease and the treatment a patient is offered.
Each cohort in the study will investigate a variety of wearable vital signs monitors in different patient groups undergoing different treatments. A common data collection platform will be used for all cohorts with a modular design that allows data collection to be adapted slightly to meet specific needs for each cohort.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
The inclusion criteria for each cohort of the EMBRaCE-GM study are specified in cohort specific documentation accompanying this application. Cohort 1 & Cohort 2 Individuals are excluded from the study if any of the following criteria apply: - Patients unable to give informed consent. - Patients in whom treatment is limited to “best supportive care” - Patients with cognitive or sensory deficits that would prevent them from following instructions and using the wearable device correctly/as instructed. - Patients for whom there is no suitably sized OURA ring or Withings ScanWatch available at the time of screening*. - Patients who are non-English speakers – an essential requirement to interact with the wearable device apps and complete the web-based surveys that form part of the study. Cohort 3 Individuals are excluded from the study if any of the following criteria apply: - Patients unable to give informed consent. - Patients in whom treatment is limited to “best supportive care” - Known allergy or history of contact dermatitis to medical adhesives. - Patients with pacemakers, implantable defibrillators or neurostimulators. - Patients with prion related diseases e.g., Spongiform Encephalopathies - Patients with cognitive or sensory deficits that would prevent them from following instructions and using the wearable device correctly/as instructed. - Patients for whom there is no suitably sized OURA ring or Withings ScanWatch available at the time of screening*. - Patients who are non-English speakers – an essential requirement to interact with the wearable device apps and complete the web-based surveys that form part of the study. For all cohorts * It is essential that participants wear appropriately sized OURA rings and Withings ScanWatches to ensure that they are comfortable and that the data collected is accurate. The study has purchased enough rings and watches to ensure that the majority of participants can be easily accommodated but on rare occasions a suitably sized device may not be available.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Corie
Jackson
corie.jackson@mft.nhs.uk
Dr
Anthony
Wilson
anthony.wilson@mft.nhs.uk
Hayley
Brooks
hayley.brooks@mft.nhs.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by MANCHESTER UNIVERSITY NHS FOUNDATION TRUST and funded by NHS ENGLAND; Innovate UK; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 50147
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
